Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective estrogen receptor modulators: a look ahead.

B H Mitlak1, F J Cohen

  • 1Indiana University School of Medicine, Indianapolis, USA. b.mitlak@lilly.com,fjcohen@lilly.com

Drugs
|June 3, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2015
Same author

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2011
Same author

The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES).

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2010
Same author

Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2008
Same author

Beyond hip: importance of other nonspinal fractures.

The American journal of medicine·2007
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Selective estrogen receptor modulators (SERMs) offer benefits for postmenopausal women, including protection against osteoporosis and breast cancer. Newer SERMs, like raloxifene, provide advantages without endometrial stimulation risks.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Oncology

Background:

  • Selective estrogen receptor modulators (SERMs) are compounds targeting estrogen receptors (ER).
  • SERMs are investigated for aging-related conditions like cancer, osteoporosis, and cardiovascular disease.
  • Existing SERMs include tamoxifen, toremifene, raloxifene, and others with diverse chemical structures.

Purpose of the Study:

  • To review the therapeutic applications and tissue-specific effects of SERMs.
  • To compare the benefits and risks of first-generation SERMs (e.g., tamoxifen) with newer agents (e.g., raloxifene).
  • To highlight the potential of SERMs in hormone replacement therapy alternatives.

Main Methods:

  • Literature review of SERM clinical data and pharmacological profiles.

Related Experiment Videos

  • Comparative analysis of SERM efficacy in treating breast cancer and osteoporosis.
  • Evaluation of SERM effects on bone mineral density, lipids, endometrium, and thromboembolism risk.

    • Main Results:

    • Tamoxifen and toremifene treat breast cancer, improve bone density and lipids, but stimulate the endometrium.
    • Raloxifene prevents osteoporosis, improves bone density, lipids, and reduces breast cancer incidence without endometrial stimulation.
    • SERMs, like estrogen, carry an increased risk of venous thromboembolism.

    Conclusions:

    • SERMs provide estrogen-like benefits for postmenopausal women while mitigating risks like breast cancer.
    • Newer SERMs, such as raloxifene, address concerns of endometrial stimulation associated with earlier agents.
    • The success of SERMs paves the way for targeted therapies modulating nuclear receptor activity.